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Background
Dicamba (3,6-dichloro-2-methoxybenzoic
acid) is a benzoic acid herbicide used to control
annual and perennial broadleaf weeds in grain
crops, grasslands, and non-crop areas such as
fence rows and roadways. Dicamba may be
used in combination with other herbicides,
such as 2,4-dichlorophenoxyacetic acid (2,4-D)
or atrazine. In 2001 Dicamba ranked 24th of
the 25 most commonly used agricultural pesti-
cides with 7–10 million pounds applied, and
7th of the 10 most commonly used home and
garden pesticides (Kiely et al. 2004).
Dicamba was ﬁrst registered for use in 1967
(National Pesticide Information Center 2005).
The U.S. Environmental Protection Agency
(EPA) has classiﬁed this general use pesticide as
toxicity class III—slightly toxic (Extension
Toxicology Network 1996), and as a Group D
carcinogen: “not classiﬁable as to human car-
cinogenicity” (U.S. EPA 2004). There is no
experimental evidence that dicamba is muta-
genic or carcinogenic (Extension Toxicology
Network 1996; U.S. EPA 2005), although rats
fed dicamba at high levels over long periods
experienced liver changes and decreased body
weight (Edson and Sanderson 1965). Limited
animal evidence suggests that dicamba could
induce tumors through epigenetic mechanisms
(Espandiari et al. 1998, 1999). 
In epidemiologic studies, occupational use
of dicamba has been associated with non-
Hodgkin lymphoma (NHL; McDufﬁe et al.
2001) and multiple myeloma (Burmeister
1990). More recently, in the Agricultural
Health Study (AHS) cohort, dicamba was
associated with an increased risk of lung can-
cer in a nested case–control analysis (Alavanja
et al. 2004). Dicamba has been found in car-
pet dust samples, with higher levels from
states with higher prevalence of lawn and gar-
den use (Colt et al. 2005), and in 1.4% of
urine samples collected between 1976 and
1980 from 6,990 participants in the Second
National Health and Nutrition Examination
Survey (Kutz et al. 1992). 
Despite its common use and some epi-
demiologic evidence that suggests increased
cancer risk, existing evaluations of dicamba-
related health effects are inadequate. In an
effort to add to existing knowledge, as well as
follow-up on the suggested association with
lung cancer previously observed in this cohort,
we investigated site-speciﬁc cancer incidence
and risk among pesticide applicators exposed
to dicamba in the AHS cohort. 
Materials and Methods
Cohort enrollment and follow-up. The AHS
is a prospective cohort study of 57,311 private
and commercial pesticide applicators in Iowa
and North Carolina recruited between 1993
and 1997 (AHS 2006b). Cohort members
were matched to cancer registry ﬁles in Iowa
and North Carolina for case identification
and to state death registries and the National
Death Index (Centers for Disease Conrol and
Prevention 2006) to ascertain vital status. We
included incident cancers diagnosed between
date of enrollment and 31 December 2002.
Cancers were coded according to the
International Classification of Diseases for
Oncology (ICD-O-2; New South Wales
Department of Health 2000). Surviving
cohort members no longer residing in Iowa
or North Carolina were identified through
current address records of the Internal
Revenue Service, state motor vehicle registra-
tion ofﬁces, and pesticide license registries of
state agricultural departments. These individ-
uals were censored from cancer incidence fol-
low-up on the dates they departed Iowa or
North Carolina. The average period of fol-
low-up time was 7.3 years. This study was
approved by all appropriate Institutional
Review Boards. Verbal informed consent was
obtained from all participants. 
Exposure assessment. A self-administered
enrollment questionnaire sought comprehen-
sive information on use of 22 specific pesti-
cides, ever/never use information for 28
additional pesticides, pesticide mixing and
application methods, repair of application
equipment, use of personal protective equip-
ment (PPE), and demographic and lifestyle
characteristics such as smoking status, alcohol
consumption, and personal and family medical
histories. This questionnaire may be accessed
at the AHS website (AHS 2006a). 
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BACKGROUND: Dicamba is an herbicide commonly applied to crops in the United States and abroad.
We evaluated cancer incidence among pesticide applicators exposed to dicamba in the Agricultural
Health Study, a prospective cohort of licensed pesticide applicators in North Carolina and Iowa. 
METHODS: Detailed pesticide exposure information was obtained through a self-administered ques-
tionnaire completed from 1993 to 1997. Cancer incidence was followed through 31 December 2002
by linkage to state cancer registries. We used Poisson regression to estimate rate ratios and 95% con-
ﬁdence intervals for cancer subtypes by tertiles of dicamba exposure. Two dicamba exposure metrics
were used: lifetime exposure days and intensity-weighted lifetime exposure days (lifetime days ×
intensity score). 
RESULTS: A total of 41,969 applicators were included in the analysis, and 22,036 (52.5%) reported
ever using dicamba. Exposure was not associated with overall cancer incidence nor were there
strong associations with any specific type of cancer. When the reference group comprised low-
exposed applicators, we observed a positive trend in risk between lifetime exposure days and lung
cancer (p = 0.02), but none of the individual point estimates was signiﬁcantly elevated. We also
observed signiﬁcant trends of increasing risk for colon cancer for both lifetime exposure days and
intensity-weighted lifetime days, although these results are largely due to elevated risk at the highest
exposure level. There was no apparent risk for non-Hodgkin lymphoma. 
CONCLUSIONS: Although associations between exposure and lung and colon cancer were observed,
we did not ﬁnd clear evidence for an association between dicamba exposure and cancer risk. 
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analysis: lifetime exposure days and intensity-
weighted lifetime exposure days. We esti-
mated the number of lifetime exposure days
to dicamba on the basis of the number of
years applied and the frequency of applica-
tion, using the midpoints of the questionnaire
categories for total years of use and days per
year of use. Lifetime exposure days were
grouped into tertiles on the basis of the distri-
bution among all cancer cases combined. To
more finely explore potential dose–response
curves, we divided the highest tertile at the
median, producing the following categories
for lifetime exposure days: No exposure, 1 to
< 20 days, 20 to < 56 days, 56 to < 116 days,
and ≥ 116 days.
To account for factors that may increase
or decrease exposure, we incorporated the
AHS exposure-intensity algorithm that is
based on the following formula: Intensity
level = [(mixing status + application method +
equipment repair status) × personal protective
equipment (PPE) score] (Dosemeci et al.
2002). Scores were assigned to each of the
four factors that the formula comprises, which
served to weight each factor according to each
possible outcome defined by what was
reported on the enrollment questionnaire. For
example, mixing status was a three-level vari-
able based on never mixing, personally mixing
< 50% of the time, and personally mixing
> 50% of the time (Mix score = 0, 3 ,9,
respectively). Pesticides are typically purchased
in concentrated form and must be diluted
prior to application, and the diluted material
is then transferred to application containers.
This mixing and loading process provides
opportunities for greater pesticide exposure
due to contact with contaminated surfaces,
splashes, and spills. 
Application method was a six-level vari-
able which, for herbicides, was based on
never applying, aerial application or distribu-
tion of tablets, application in furrow, use of
tractor-mounted boom sprayer, use of back-
pack, and use of hand spray (application
score = 0, 1, 2, 3, 8, 9, respectively). The use
of backpack sprayers or hand sprayers to
apply pesticides may result in higher dermal
exposures than use of a tractor-mounted
boom sprayer because the backpack and hand
spray wands are in direct contact with the
applicator’s hands or body. Equipment repair
status was a two-level variable based on not
repairing or repairing (repair score = 0, 2,
respectively). PPE was an eight-level variable
based on four groups of PPE combinations
(PPE = 0 if never used PPE; PPE = 1 if wore
face shield/goggles or fabric/leather gloves or
other protective clothing; PPE = 2 if wore
cartridge respirator/gas mask or disposable
outer clothing; and PPE = 3 if wore chemical
resistant rubber gloves). 
Intensity-weighted lifetime exposure days
is the product of lifetime exposure days and
intensity level, and was categorized into tertiles
with the upper tertile further divided at the
median. Categories included no exposure, 1 to
< 86.6 intensity-weighted days, 86.6 to
< 344.3 intensity-weighted days, 344.3 to
< 739.2 intensity-weighted days, and ≥ 739.2
intensity-weighted days.
Data analysis. Rate ratios (RRs) and 95%
confidence intervals (CIs) were calculated to
estimate risk of various cancers associated with
dicamba exposure. All models were based on
the Poisson distribution and included ﬁrst pri-
mary incident cancer cases. Individuals with
cancer prevalent at the time of enrollment
(n = 1,075) were excluded from the analysis.
Of the remaining participants, 6,362 were
missing information about dicamba use and
were also excluded. Because there were only
four exposed cancer cases, we were unable to
adequately examine risk among the 1,297
female applicators. A total of 41,969 male
applicators remained in the analysis after los-
ing 6,608 additional participants who were
missing one or more covariates.
We examined risk for all cancer sites clas-
sified under ICD-O-2 (New South Wales
Department of Health 2000). In the tables we
present only cancers for which there were at
least ﬁve cases in each exposure category. All
models were adjusted for baseline variables:
age at enrollment (< 40, 40–49, 50–59, ≥ 60
years), race (white, nonwhite), alcohol con-
sumption during the year of enrollment (ever,
never), smoking status at enrollment (never,
low, and high based on the median value of
pack-years among smokers), family history of
cancer in ﬁrst degree relatives (yes, no), appli-
cator status (private, commercial), and state of
residence (Iowa, North Carolina). Because of
potential concurrent exposure to other pesti-
cides, we examined the impact of adjusting
for pesticides highly correlated with use of
dicamba, as well as adjusting all RRs for total
lifetime days of pesticide use as a continuous
variable (Alavanja et al. 2004). In addition to
tertiles of lifetime exposure days and inten-
sity-weighted lifetime exposure days, we
examined the association between cancer 
risk and tertiles of each exposure component: 
days per year of dicamba use, total years of
dicamba use, and the dicamba intensity score.
We analyzed exposure–response trends by
including the midpoint of each tertile as a
continuous variable in the model and testing
for the statistical signiﬁcance of the slope. 
To evaluate the most appropriate reference
group, we examined a number of characteris-
tics that may be related to intensity of lifetime
days of dicamba exposure, which was divided
into three categories: those who never applied
dicamba, applicators in the lowest tertile of
lifetime exposure days (low-exposed), and
applicators in the top two tertiles of lifetime
exposure days (high-exposed). Differences
with respect to these and other baseline char-
acteristics may introduce residual confounding
from a variety of unidentified sources. To
avoid this, we assumed that applicators with
baseline characteristics more similar to those
of the applicators in the higher exposure group
would be most appropriate as a reference
group for the Poisson regression analyses
(Rusiecki et al. 2004).
Results
Selected characteristics of the dicamba-exposed
and non-dicamba-exposed applicators are pre-
sented in Table 1. Among 41,969 participants
with complete exposure information, 22,036
(52.5%) reported ever having personally
applied or mixed dicamba and had complete
data on lifetime days of exposure. The study
population comprised primarily white, male
private applicators. In both the exposed and
nonexposed groups, about half of the partici-
pants reported that they had never smoked.
High-exposed applicators tended to be more
similar to low-exposed applicators than never-
exposed applicators with respect to baseline
characteristics of age, race, state of residence,
smoking status, education, alcohol consump-
tion during year of enrollment, family history
of cancer, applicator type, living or working on
a farm at enrollment, and corn and soybean
production. Despite differences between the
never-exposed and low-exposed groups, results
differed only slightly when either was used as
the reference group, and we provide results for
both analyses. 
We found no strong associations between
any cancer site and dicamba exposure for either
lifetime exposure days or intensity-weighted
lifetime exposure days (Tables 2 and 3). We
did observe a trend of increasing lung cancer
risk with increasing lifetime exposure days
when the referent group was low-exposed par-
ticipants (p-value for trend = 0.02), with a RR
of 2.16 (95% CI, 0.97–4.82) for the upper
half of the highest tertile. The number of non-
smoking, dicamba-exposed lung cancer cases
(n = 5) was too small to assess risk among non-
smokers. In an analysis based on intensity-
weighted exposure days, those with exposure in
the top two tertiles had nearly twice the risk as
those with low exposure, but no dose response
was evident. There was no evidence of
increased lung cancer risk with either lifetime
exposure days or intensity-weighted lifetime
days when applicators unexposed to dicamba
served as the referent. 
We also observed significant trends of
increasing risk for colon cancer for both life-
time exposure days and intensity-weighted
lifetime days when the referent group com-
prised low-exposed applicators. However, only
RRs for the highest exposure category were
Samanic et al.
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1.40–7.73; p-trend = 0.02; intensity-weighted
lifetime days RR = 2.57; 95% CI, 1.28–5.17;
p-trend = 0.002). This trend was not observed
when the referent group comprised applicators
who never used dicamba. There were no dif-
ferences in risk for lung or colon cancer when
we restricted the analysis to applicators who
ﬁrst applied dicamba prior to 1990 (data not
shown). NHL was not associated with
dicamba exposure, and there were too few
cases of multiple myeloma to analyze. 
We attempted to stratify risk for all cancers
by state of residence (Iowa vs. North Carolina)
and applicator type (private vs. commercial)
but were unable to provide stable estimates for
most cancers in North Carolina because of
small numbers. For example, there were only 6
dicamba-exposed colon cancer cases in North
Carolina, and 12 dicamba-exposed lung cancer
cases. Given that a large proportion of partici-
pants with no dicamba exposure came from
North Carolina (50%) and the majority of our
highly exposed participants came from Iowa
(92%), state of residence is clearly associated
with dicamba exposure. The trends in risk for
lung and colon cancer did not significantly
change after restricting the analyses to the state
of Iowa.
We also examined risk for each cancer site
for each of the three components of the expo-
sure algorithm grouped into tertiles: days per
year of dicamba use, total years of dicamba
use, and the dicamba intensity score. We
observed no association between any of these
components and risk for any cancer site,
except for lung cancer, where the RR was 2.07
(95% CI, 1.05–4.08) for participants in the
top tertile (> 15.5 years of dicamba exposure;
n = 13 exposed cases) relative to that for unex-
posed participants (data not shown). Because
dicamba is often used in combination with the
herbicides 2,4-D, atrazine, or glyphosate, we
attempted to examine dicamba-associated risk
of lung and colon cancers stratiﬁed by never/
ever use of these three herbicides. However, a
large proportion of applicators reported ever
using 2,4-D, atrazine, and glyphosate (78, 72,
and 77%, respectively), so the numbers of
dicamba-exposed cases in the never-used strata
were too small to provide a meaningful com-
parison of risk between strata. 
Last, we attempted to adjust for con-
founding due to concurrent exposure to other
pesticide in multiple ways. We examined the
effect of adjusting for ever/never use of nine
other pesticides most highly correlated with
dicamba use. None of the individual pesti-
cides substantially altered the trends in risk.
When all nine pesticide variables were entered
into the models simultaneously, the magni-
tude of adjustment was similar to when we
used total lifetime days of any pesticide use in
continuous form. For the sake of efficiency
we selected total lifetime days of any pesticide
use as the main adjustment variable. We also
subtracted the number of dicamba lifetime
exposure days from the total lifetime days of
any pesticide use. This did not substantially
alter the trends in risk for any of the cancer
sites we examined; almost all point estimates
remained the same.
Discussion
Our study is the largest study to date of can-
cer risk associated with exposure to the herbi-
cide dicamba. We observed a suggestion of
increased risk for lung and colon cancer when
the referent group comprised low-exposed
applicators but not when the referent group
comprised unexposed applicators. With fur-
ther follow-up and accumulation of exposed
cases, we believe we will better understand
this phenomenon. 
The association with lung cancer we
observed in our study is similar to that
reported in an earlier nested case–control study
in the AHS cohort. Alavanja et al. (2004)
observed a positive trend in risk for lung cancer
with lifetime exposure days of dicamba, for the
highest exposure tertile (highest tertile divided
at the median) relative to the lowest exposure
tertile [odds ratio (OR) = 1.0, 1.3, 1.7, 3.1;
p-value for trend = 0.04). A signiﬁcant trend
was not observed when the investigators used
unexposed participants as the referent group
(OR = 1.0, 0.7, 0.9, 1.1, 1.6; p-value for
trend = 0.15). When we modeled risk of lung
cancer associated with lifetime dicamba expo-
sure days using the low exposed as the referent
group and the same tertile cut points used in
the analysis conducted by Alavanja et al.
(2004), not surprisingly, our results were very
similar (OR = 1.0, 1.1, 1.6, 2.1; p-value for
Cancer and dicamba exposure
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Table 1. Selected characteristics of male applicators enrolled in the Agricultural Health Study categorized
by dicamba exposure, 1993–2001 [no. (%)].
Unexposed Low-exposeda High-exposedb
Characteristic (n = 19,933) (n = 6,116) (n = 15,920)
Age (years)
< 40 7,325 (36.7) 2,059 (33.7) 5,190 (32.6)
40–49 5,234 (26.3) 1,838 (30.0) 5,269 (33.1)
50–59 3,855 (19.3) 1,235 (20.2) 3,349 (21.0)
≥ 60 3,519 (17.7) 984 (16.1) 2,112 (13.3)
Race
White 19,362 (97.1) 6,094 (99.6) 15,850 (99.6)
Nonwhite 571 (2.9) 22 (0.4) 70 (0.4)
State
Iowa 9,911 (49.7) 5,350 (87.5) 14,693 (92.3)
North Carolina 10,022 (50.3) 766 (12.5) 1,227 (7.7)
Smoking
Never 10,359 (52.0) 3,736 (61.2) 9,153 (57.5)
Former 4,710 (23.6) 1,378 (22.5) 3,716 (23.3)
Current 4,864 (24.4) 1,002 (16.4) 3,051 (19.2)
Education
≤ High School 11,005 (55.2) 3,042 (49.7) 8,175 (51.3)
> High School 8,490 (46.2) 2,983 (48.8) 7,541 (47.4)
Missing 438 (2.2) 91 (1.5) 204 (1.3)
Alcohol consumptionc
No 7,518 (37.7) 1,521 (24.9) 3,093 (19.4)
Yes 12,415 (62.3) 4,595 (75.1) 12,827 (80.6)
Family history, cancer
No 12,332 (61.9) 3,510 (57.4) 9,201 (57.8)
Yes 7,601 (38.1) 2,606 (42.6) 6,719 (42.2)
Applicator type
Private 11,822 (59.3) 5,277 (86.3) 13,679 (85.9)
Commercial 8,111 (40.7) 839 (13.7) 2,241 (14.1)
Own or work on farmc
Never 2251 (11.3) 275 (4.5) 1,281 (8.0)
Ever 17,568 (88.1) 5834 (95.4) 1,4615 (91.8)
Missing 114 (0.6) 7 (0.1) 24 (0.2)
Field corn production
No 8,111 (40.7) 839 (13.7) 2,241 (14.1)
Yes 11,822 (59.3) 5,277 (86.3) 13,679 (85.9)
Soybean production
No 8,403 (42.2) 1,324 (21.6) 3,155 (19.8)
Yes 11,530 (57.8) 4,792 (78.4) 12,765 (80.2)
Person-years (total) 148,314.7 44,557.4 115,806.4
Follow-up (years)d 7.4 ± 1.5 7.3 ± 1.4 7.3 ± 1.4
Total lifetime days of 345.0 ± 617.2  278.0 ± 434.9 472.9 ± 615.6
pesticide applicationd
aFirst tertile of lifetime exposure-days (years of use × days per year). bSecond and third tertiles of lifetime exposure days.
cDuring enrollment year. dMean ± SD.trend = 0.02). There is no prior evidence that
suggests an association between dicamba
exposure and colon cancer.
Exposure to dicamba has been associated
with increased risk for NHL in a few previous
case–control studies. In a case–control study
of NHL and pesticide exposure conducted in
Canada, information on pesticide exposure
was collected through a combination of
mailed questionnaires and telephone inter-
views (McDufﬁe et al. 2001). After adjusting
for demographic characteristics, family history
of cancer in a ﬁrst-degree relative, and history
of selected medical conditions, increasing
days per year of dicamba application was asso-
ciated with an increased risk of NHL (OR =
1.7; 95% CI, 1.0–2.8). When exposure to
dicamba as a general class was evaluated,
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Table 2. Rate ratios and 95% CI for selected cancers by tertiles of total dicamba
lifetime exposure days among male pesticide applicators in the Agricultural
Health Study.a
Dicamba exposure
No exposure—referent Low exposed—referent
Cancer site Cases (n) RR 95% CI RR 95% CI
All cancers
No exposure 887 1.00
1 to < 20 227 0.90 0.77–1.05 1.00
20 to < 56 254 1.00 0.82–1.11 1.07 0.89–1.28
56 to < 116 169 0.90 0.73–1.03 0.97 0.79–1.19
≥ 116 157 1.02 0.85–1.23 1.18 0.94–1.46
p = 0.69 p = 0.18
Colon
No exposure 76 1.00
1 to < 20 9 0.42 0.20–0.85 1.00
20 to < 56 20 0.88 0.52–1.50 2.07 0.94–4.57
56 to < 116 13 0.81 0.43–1.51 1.85 0.79–4.37
≥ 116 17 1.42 0.78–2.58 3.29 1.40–7.73
p = 0.10 p = 0.02
Lung
No exposure 95 1.00
1 to < 20 14 0.84 0.45–1.54 1.00
20 to < 56 11 0.64 0.33–1.26 0.82 0.36–1.85
56 to < 116 12 0.96 0.50–1.85 1.29 0.58–2.89
≥ 116 15 1.47 0.79–2.72 2.16 0.97–4.82
p = 0.13 p = 0.02
Prostate
No exposure 343 1.00
1 to < 20 106 1.00 0.80–1.27 1.00
20 to < 56 102 0.94 0.74–1.20 0.94 0.72–1.24
56 to < 116 76 0.96 0.73–1.25 0.95 0.71–1.29
≥ 116 67 1.08 0.81–1.46 1.10 0.79–1.53
p = 0.45 p = 0.45
Bladder
No exposure 43 1.00
1 to < 20 6 0.51 0.21–1.25 1.00
20 to < 56 9 0.66 0.31–1.43 1.26 0.44–3.55
56 to < 116  6 0.59 0.24–1.45 1.11 0.36–3.47
≥ 116 8 0.82 0.36–1.88 1.39 0.44–4.42
p = 0.66 p = 0.66
Melanoma
No exposure 32 1.00
1 to < 20 10 0.97 0.46–2.06 1.00
20 to < 56 18 1.59 0.84–3.00 1.65 0.76–3.60
56 to < 116 6 0.72 0.29–1.81 0.75 0.27–2.07
≥ 116 6 0.83 0.33–2.13 0.93 0.32–2.71
p = 0.51 p = 0.48
Non-Hodgkin lymphoma
No exposure 39 1.00
1 to < 20 18 1.75 0.96–3.21 1.00
20 to < 56 14 1.29 0.66–2.53 0.73 0.36–1.48
56 to < 116 7 0.92 0.39–2.16 0.54 0.22–1.31
≥ 116 7 1.19 0.50–2.85 0.76 0.30–1.97
p = 0.92 p = 0.71
All hematopoieticb
No exposure 82 1.00
1 to < 20 31 1.38 0.89–2.15 1.00
20 to < 56 32 1.37 0.87–2.14 0.97 0.59–1.59
56 to < 116 16 0.96 0.54–1.70 0.69 0.37–1.26
≥ 116 17 1.31 0.74–2.31 0.99 0.53–1.87
p = 0.66 p = 0.99
aAdjusted for age, state of residence, smoking (pack-years), education, family history of
cancer, and total lifetime days of pesticide application; upper tertile divided at the median.
bIncludes leukemia, multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphoma.
Table 3. Rate ratios and 95% CI for selected cancers by tertiles of dicamba
intensity-weighted lifetime exposure days among male pesticide applicators in
the Agricultural Health Study.a
Dicamba exposure
No exposure—referent Low exposed—referent
Cancer site Cases (n) RR 95% CI RR 95% CI
All cancers
No exposure  888 1.00
1 to < 86.6 251 0.90 0.80–1.00 1.00
86.6 to < 344.25 278 1.00 0.84–1.13 1.11 0.93–1.32
344.25 to < 739.2 131 0.90 0.73–1.08 1.02 0.82–1.26
≥ 739.2 144 1.00 0.82–1.20 1.15 0.93–1.43
p = 0.91 p = 0.35
Colon
No exposure  76 1.00
1 to < 86.6 16 0.64 0.36–1.14 1.00
86.6 to < 344.25 17 0.70 0.40–1.22 1.04 0.52–2.06
344.25 to < 739.2 6 0.50 0.21–1.17 0.74 0.29–1.91
≥ 739.2 20 1.76 1.00–3.07 2.57 1.28–5.17
p = 0.02 p = 0.002
Lung
No exposure  95 1.00
1 to < 86.6 11 0.61 0.31–1.21 1.00
86.6 to < 344.25 20 1.07 0.62–1.84 1.92 0.89–4.11
344.25 to < 739.2 10 1.03 0.51–2.08 1.90 0.78–4.60
≥ 739.2 11 1.10 0.56–2.18 2.20 0.90–5.38
p = 0.58 p = 0.21
Prostate
No exposure  343 1.00
1 to < 86.6 115 0.97 0.77–1.21 1.00
86.6 to < 344.25 110 0.95 0.75–1.20 1.00 0.75–1.27
344.25 to < 739.2 59 1.03 0.77–1.37 1.07 0.78–1.46
≥ 739.2 61 1.11 0.83–1.50 1.17 0.84–1.62
p = 0.38 p = 0.27
Bladder
No exposure  43 1.00
1 to < 86.6 6 0.46 0.19–1.11 1.00
86.6 to < 344.25 13 0.89 0.45–1.74 1.95 0.74–5.13
344.25 to < 739.2 6 0.77 0.31–1.90 1.70 1.54–5.27
≥ 739.2 4 0.43 0.15–1.25 0.94 0.26–3.41
p = 0.20 p = 0.34
Melanoma
No exposure  32 1.00
1 to < 86.6 10 0.84 0.40–1.80 1.00
86.6 to < 344.25 18 1.51 0.80–2.84 1.80 0.83–3.91
344.25 to < 739.2 7 1.06 0.45–2.53 1.27 0.48–3.35
≥ 739.2 5 0.77 0.28–2.07 1.00 0.32–2.90
p = 0.60 p = 0.54
Non-Hodgkin lymphoma
No exposure  39 1.00
1 to < 86.6 17 1.43 0.77–2.67 1.00
86.6 to < 344.25 18 1.55 0.83–2.87 1.08 0.56–2.10
344.25 to < 739.2 4 0.67 0.23–1.91 0.46 0.15–1.37
≥ 739.2 6 1.07 0.43–2.67 0.74 0.29–1.93
p = 0.68 p = 0.51
All hematopoieticb
No exposure  82 1.00
1 to < 86.6 31 1.22 0.78–1.90 1.00
86.6 to < 344.25 35 1.41 0.91–2.18 1.13 0.70–1.84
344.25 to < 739.2 16 1.23 0.69–2.17 1.00 0.54–1.82
≥ 739.2 12 1.00 0.51–1.86 0.83 0.41–1.66
p = 0.81 p = 0.46
aAdjusted for age, state of residence, smoking (pack-years), education, family history of
cancer, and total lifetime days of pesticide application; upper tertile divided at the median.
bIncludes leukemia, multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphoma.
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which included dicamba-only products as well
as mixtures of dicamba and glyphosate and
mixtures of dicamba, 2,4-D and mecoprop,
NHL risk increased slightly with increasing
days per year of application (OR = 1.9;
95 %CI, 1.3–2.7). Conversely, results from a
case–control study of NHL and farming in the
United States suggested no association
between risk of NHL and ever handling either
benzoic acids as a class (OR = 1.3; 95% CI,
0.9–1.9) or dicamba in particular (OR = 1.2;
95% CI, 0.7–2.0) (Cantor et al. 1992). After
restricting the analyses to pesticides handled
prior to 1965, risk for NHL was elevated
among dicamba users (OR = 2.8; 95% CI,
0.96–8.1). Our prospective data do not pro-
vide evidence of an association between
dicamba and NHL. Our findings, however,
may be influenced by the small number of
cases and relatively short follow-up time. 
Results from other studies provide no evi-
dence for an association between dicamba and
risk of leukemia (OR = 0.7; 95% CI,
0.4–1.4) (Brown et al. 1990) or multiple
myeloma (OR = 1.3; 95% CI, 0.6–2.8)
(Brown et al. 1993). However, Burmeister
(1990) reported a nonsignificant, marginal
association between exposure to benzoic acids
as a class and risk of multiple myeloma (OR =
1.22; confidence interval/p-value not
reported). In our study, exposure to dicamba
is likely to be a combination of exposure to
dicamba-only products as well as to dicamba
mixtures, making it difficult to disentangle
the effect of dicamba from other pesticides
included in dicamba mixtures. After stratify-
ing dicamba models for lung and colon can-
cers by never/ever use of 2,4-D, atrazine, and
glyphosate (three herbicides commonly mixed
with dicamba), there was no evidence for
either increased risk among dicamba-only
users, or for increased risk among participants
who also used 2,4-D, atrazine, or glyphosate.
Because this analysis is based on information
pertaining to ever/never use of individual pes-
ticide active ingredients, however, we were
unable to unambiguously differentiate
between use of dicamba-only products and
dicamba mixtures at this time. 
There is little experimental evidence to
suggest that dicamba is carcinogenic or muta-
genic (U.S. EPA 1999). Feeding studies in
rats, mice, dogs, and rabbits have shown no
increased incidence of tumors (Extension
Toxicology Network 1999). There is evi-
dence that dicamba acts as a peroxisome pro-
liferator (PP) by increasing fatty acyl–
coenzyme A oxidase activity in the livers of
rats and activating the peroxisome prolifera-
tor receptor in a dose-dependent fashion
(Espandiari et al. 1998, 1999). It is thought
that PPs may induce liver tumors in rats
through mechanisms related to oxidative
stress, inducing replicative DNA synthesis, or
by promoting growth of preneoplastic lesions
(Espandiari et al. 1998). Dicamba induced
DNA damage in one study of rats (Perocco
et al. 1990). In another study of mice,
dicamba caused mortality in two of four mice
injected with dicamba but did not increase
xenobiotic-metabolizing activities in the two
surviving mice (Moody et al. 1991). Few epi-
demiologic studies on the effect of PPs on
humans have been conducted (Nakajima
et al. 2002), but there are marked species dif-
ferences in response to PPs (Lai 2004).
Humans seem to exhibit a weak response to
PP chemicals (including certain pesticides,
industrial solvents, and hypolipidemic
drugs), which may be due to low levels of
peroxisome proliferator-activated receptor
alpha in human liver (Lai 2004; Maloney
and Waxman 1999).
The Agricultural Health Study is the
largest study to date of pesticide applicators
exposed to dicamba. The potential for recall
bias is minimal, as exposure information was
collected prior to cancer diagnosis. AHS
applicators have been shown to provide reli-
able information about their histories of pes-
ticide use (Blair et al. 2002; Hoppin et al.
2002), although misclassification can occur.
Misclassification in a prospective study is
likely to be nondifferential with regard to
cancer occurrence and, although it could
diminish estimates of relative risk, it is
unlikely to create false positives (Checkoway
et. al. 2004).
Our results may be affected by simultane-
ous exposure to other pesticides of varying
intensity that has changed over time,
although we attempted to account for this by
adjusting for total lifetime days of any pesti-
cide use. In addition, we could not differenti-
ate use of dicamba-only products from
dicamba mixtures. This is one of the biggest
challenges in conducting epidemiologic
research on pesticides, as many pesticides are
most often used in combination with others
in complex mixtures and not as individual
pesticides. The existing toxicologic data, how-
ever, pertain to dicamba as an individual
chemical. Our findings may also be limited
because of a relatively short period of follow-
up and small numbers of cases for some can-
cer sites. Because of the lack of consistency
among results from the four evaluations of
exposure metric and referent type for lung
and colon cancer, these findings should be
interpreted with caution. 
Despite these limitations, our prospective
study of cancer incidence among dicamba-
exposed pesticide applicators provided an
opportunity afforded in few other studies to
evaluate cancer risks associated with exposure
to dicamba while adjusting for lifetime use of
other pesticides and lifestyle factors. We did
not detect much evidence for an association
between dicamba exposure and any of the can-
cer sites investigated, but the patterns of associ-
ations observed for lung and colon cancers
warrant further attention. We will re-examine
dicamba in the future when larger numbers
will allow for a more comprehensive evaluation
of lung and colon cancer, as well as additional
cancer sites.
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